Dataset Information

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy.

ABSTRACT: The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights.

SUBMITTER: Beck J

PROVIDER: S-EPMC6343606 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16<sup>th</sup> Annual Meeting of the Association for Cancer Immunotherapy.

Beck Jan J Birtel Matthias M Reidenbach Daniel D Salomon Nadja N Diken Mustafa M

Human vaccines & immunotherapeutics 20180829 12

The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights. ...[more]

PMID: 30111232

Similar Datasets

Project description:Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinations in the clinic may still face formidable challenges in regulatory, drug-availability and intellectual property aspects. The 2011 SITC annual meeting hosted a workshop on combination immunotherapy to discuss: 1) the most promising combinations found in the laboratory; 2) early success of combination immunotherapy in clinical trials; 3) industry perspectives on combination approaches, and 4) relevant regulatory issues. The integrated theme was how to accelerate the implementation of efficacious combined immunotherapies for cancer patients. Rodent animal models are providing many examples of synergistic combinations that typically include more than two agents. However, mouse and human immunology differ in a significant number of mechanisms and hence we might be missing opportunities peculiar to humans. Nonetheless, incisive animal experimentation with deep mechanistic insight remains the best compass that we can use to guide our paths in combinatorial immunotherapy. Combination immunotherapy clinical trials are already in progress and preliminary results are extremely promising. As a key to translate promising combinations into clinic, real and "perceived" business and regulatory hurdles were debated. A formidable step forward would be to be able to test combinations of investigational agents prior to individual approval. Taking together the FDA and the industrial perspective on combinatorial immunotherapy, the audience was left with the clear message that this is by no means an impossible task. The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace.

Dataset Information

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy.

Publications

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16<sup>th</sup> Annual Meeting of the Association for Cancer Immunotherapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure